6 hours Ago By ABMN Staff
Raymond James Financial Inc. bought a new position in Genmab A/S ( NASDAQ:GMAB – Free Report ) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 118,002 shares of the company’s stock, valued at approximately $2,463,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GMAB. Brandywine Global Investment Management LLC bought a new stake in shares of Genmab A/S in the fourth quarter worth about $33,804,000. Russell Investments Group Ltd.
lifted its holdings in Genmab A/S by 18,959.1% in the 4th quarter. Russell Investments Group Ltd.
now owns 510,784 shares of the company’s stock worth $10,660,000 after buying an additional 508,104 shares during the period. JPMorgan Chase & Co. grew its position in shares of Genmab A/S by 3,049.
3% in the 4th quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company’s stock worth $8,507,000 after buying an additional 394,670 shares during the last quarter.
Trexquant Investment LP increased its stake in shares of Genmab A/S by 495.1% during the fourth quarter. Trexquant Investment LP now owns 379,936 shares of the company’s stock valued at $7,929,000 after buying an additional 316,089 shares during the period.
Finally, ABC Arbitrage SA bought a new position in shares of Genmab A/S during the fourth quarter valued at approximately $3,692,000. 7.07% of the stock is currently owned by institutional investors.
Genmab A/S Stock Performance NASDAQ:GMAB opened at $20.79 on Wednesday. The firm has a 50-day simple moving average of $20.
41 and a two-hundred day simple moving average of $21.00. The firm has a market cap of $13.
76 billion, a P/E ratio of 11.95, a P/E/G ratio of 2.65 and a beta of 1.
07. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.
41. Wall Street Analyst Weigh In A number of research analysts have issued reports on GMAB shares. Truist Financial reduced their price objective on shares of Genmab A/S from $50.
00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th.
Sanford C. Bernstein cut Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.
00 target price for the company in a research report on Thursday, February 13th. Finally, Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock.
According to MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and a consensus target price of $39.17. Read Our Latest Report on Genmab A/S Genmab A/S Profile ( Free Report ) Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Further Reading Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S ( NASDAQ:GMAB – Free Report ).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter ..
